125 related articles for article (PubMed ID: 12394286)
1. The European NEAT program: an integrated approach using acamprosate and psychosocial support for the prevention of relapse in alcohol-dependent patients with a statistical modeling of therapy success prediction.
Pelc I; Ansoms C; Lehert P; Fischer F; Fuchs WJ; Landron F; Pires Preto AJ; Morgan MY
Alcohol Clin Exp Res; 2002 Oct; 26(10):1529-38. PubMed ID: 12394286
[TBL] [Abstract][Full Text] [Related]
2. Improvement in quality of life after treatment for alcohol dependence with acamprosate and psychosocial support.
Morgan MY; Landron F; Lehert P;
Alcohol Clin Exp Res; 2004 Jan; 28(1):64-77. PubMed ID: 14745303
[TBL] [Abstract][Full Text] [Related]
3. A pragmatic trial of acamprosate in the treatment of alcohol dependence in primary care.
Kiritzé-Topor P; Huas D; Rosenzweig C; Comte S; Paille F; Lehert P
Alcohol Alcohol; 2004; 39(6):520-7. PubMed ID: 15304381
[TBL] [Abstract][Full Text] [Related]
4. Use of acamprosate and different kinds of psychosocial support in relapse prevention of alcoholism. Results from a non-blind, multicentre study.
Soyka M; Preuss U; Schuetz C
Drugs R D; 2002; 3(1):1-12. PubMed ID: 11881521
[TBL] [Abstract][Full Text] [Related]
5. Why is disulfiram superior to acamprosate in the routine clinical setting? A retrospective long-term study in 353 alcohol-dependent patients.
Diehl A; Ulmer L; Mutschler J; Herre H; Krumm B; Croissant B; Mann K; Kiefer F
Alcohol Alcohol; 2010; 45(3):271-7. PubMed ID: 20348436
[TBL] [Abstract][Full Text] [Related]
6. Combined acamprosate and naltrexone, with cognitive behavioural therapy is superior to either medication alone for alcohol abstinence: a single centres' experience with pharmacotherapy.
Feeney GF; Connor JP; Young RM; Tucker J; McPherson A
Alcohol Alcohol; 2006; 41(3):321-7. PubMed ID: 16467406
[TBL] [Abstract][Full Text] [Related]
7. Alcohol-use disorders and depression: results from individual patient data meta-analysis of the acamprosate-controlled studies.
Lejoyeux M; Lehert P
Alcohol Alcohol; 2011; 46(1):61-7. PubMed ID: 21118900
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis.
Mann K; Lehert P; Morgan MY
Alcohol Clin Exp Res; 2004 Jan; 28(1):51-63. PubMed ID: 14745302
[TBL] [Abstract][Full Text] [Related]
9. Effect of early and late compliance on the effectiveness of acamprosate in the treatment of alcohol dependence.
Koeter MW; van den Brink W; Lehert P
J Subst Abuse Treat; 2010 Oct; 39(3):218-26. PubMed ID: 20627222
[TBL] [Abstract][Full Text] [Related]
10. Comparison of acamprosate and placebo in long-term treatment of alcohol dependence.
Whitworth AB; Fischer F; Lesch OM; Nimmerrichter A; Oberbauer H; Platz T; Potgieter A; Walter H; Fleischhacker WW
Lancet; 1996 May; 347(9013):1438-42. PubMed ID: 8676626
[TBL] [Abstract][Full Text] [Related]
11. Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study.
Namkoong K; Lee BO; Lee PG; Choi MJ; Lee E
Alcohol Alcohol; 2003; 38(2):135-41. PubMed ID: 12634260
[TBL] [Abstract][Full Text] [Related]
12. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes.
Rösner S; Leucht S; Lehert P; Soyka M
J Psychopharmacol; 2008 Jan; 22(1):11-23. PubMed ID: 18187529
[TBL] [Abstract][Full Text] [Related]
13. Acamprosate for the treatment of alcohol dependence.
Boothby LA; Doering PL
Clin Ther; 2005 Jun; 27(6):695-714. PubMed ID: 16117977
[TBL] [Abstract][Full Text] [Related]
14. Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland.
Buri C; Moggi F; Giovanoli A; Strik W
Alcohol Alcohol; 2007; 42(4):333-9. PubMed ID: 17517820
[TBL] [Abstract][Full Text] [Related]
15. Clinical predictors of outcome from an Australian pharmacological relapse prevention trial.
Morley KC; Teesson M; Sannibale C; Baillie A; Haber PS
Alcohol Alcohol; 2010; 45(6):520-6. PubMed ID: 20952764
[TBL] [Abstract][Full Text] [Related]
16. Effect of community nurse follow-up when treating alcohol dependence with acamprosate.
Pelc I; Hanak C; Baert I; Houtain C; Lehert P; Landron F; Verbanck P
Alcohol Alcohol; 2005; 40(4):302-7. PubMed ID: 15870092
[TBL] [Abstract][Full Text] [Related]
17. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol.
Paille FM; Guelfi JD; Perkins AC; Royer RJ; Steru L; Parot P
Alcohol Alcohol; 1995 Mar; 30(2):239-47. PubMed ID: 7662044
[TBL] [Abstract][Full Text] [Related]
18. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation.
Mason BJ; Goodman AM; Chabac S; Lehert P
J Psychiatr Res; 2006 Aug; 40(5):383-93. PubMed ID: 16546214
[TBL] [Abstract][Full Text] [Related]
19. A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence.
Laaksonen E; Koski-Jännes A; Salaspuro M; Ahtinen H; Alho H
Alcohol Alcohol; 2008; 43(1):53-61. PubMed ID: 17965444
[TBL] [Abstract][Full Text] [Related]
20. Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smokers.
Schmidt LG; Smolka MN
Alcohol Alcohol; 2007; 42(3):241-6. PubMed ID: 17526634
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
